Clinical trial registry record

TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration

A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Active Not Recruiting.
Evidence
Registered phase 3 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated January 7, 2025.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT05461339
Last registry update
January 7, 2025
Status
Active Not Recruiting
Phase
Phase 3
Sponsor
BioDlink Biopharm Co., Ltd.
Enrollment
488
Countries
China
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 3
Study design
RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE
Evidence population
Human clinical study registration
Participants
488
Population
ALL · 50 Years to 90 Years
Duration
2022-06-28 to 2025-02-01
Intervention
TAB014 Monoclonal Antibody Injection; Ranibizumab Injection [Lucentis]
Comparator
Ranibizumb
Outcomes measured
Evaluate the change in BCVA of the study eye from TAB014 and ranibizumab treatment groups. — At week 52; Evaluate the change in BCVA of the study eye — At week 12, 24 and 36; Evaluate the proportion of subjects with an increase in BCVA of >5, >10, and >15 in the study eye — At week 12, 24 and…; Evaluate the proportion of subjects with a BCVA loss of <5, <10, < 15 letters in the study eye — At week 12, 24 and 52; Change in central subfield thickness（CST) in the study eye — At week 12, 24, 36 and 52; Change in Choroidal Neovascularization (CNV) area of study eye — At week 12, 24 and 52
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 3A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 100%Title contains controlled term: age-related macular degeneration. Abstract contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 65%. These figures help sort records; they are not medical ratings.

vision aging
Open primary sourceExport JSON